Geode Capital Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $61.6M | Buy |
8,031,921
+111,743
| +1% | +$765K | ﹤0.01% | 1385 |
|
|
2025
Q4 | $15.7M | Buy |
7,920,178
+1,030,113
| +15% | +$2.33M | ﹤0.01% | 2142 |
|
|
2025
Q3 | $17M | Buy |
6,890,065
+1,112,796
| +19% | +$2.87M | ﹤0.01% | 2083 |
|
|
2025
Q2 | $15.3M | Buy |
5,777,269
+1,487,849
| +35% | +$4M | ﹤0.01% | 2103 |
|
|
2025
Q1 | $12.9M | Buy |
4,289,420
+448,502
| +12% | +$1.36M | ﹤0.01% | 2136 |
|
|
2024
Q4 | $9.83M | Sell |
3,840,918
-5,757
| -0.1% | -$24K | ﹤0.01% | 2387 |
|
|
2024
Q3 | $14.3M | Sell |
3,846,675
-70,819
| -2% | -$328K | ﹤0.01% | 2164 |
|
|
2024
Q2 | $24.8M | Buy |
3,917,494
+436,108
| +13% | +$2.88M | ﹤0.01% | 1818 |
|
|
2024
Q1 | $18.7M | Buy |
3,481,386
+101,922
| +3% | +$462K | ﹤0.01% | 1960 |
|
|
2023
Q4 | $17M | Buy |
3,379,464
+573,281
| +20% | +$1.8M | ﹤0.01% | 2014 |
|
|
2023
Q3 | $4.74M | Buy |
2,806,183
+75,731
| +3% | +$152K | ﹤0.01% | 2664 |
|
|
2023
Q2 | $7.59M | Buy |
2,730,452
+784,588
| +40% | +$2.22M | ﹤0.01% | 2457 |
|
|
2023
Q1 | $3.54M | Sell |
1,945,864
-84,628
| -4% | -$263K | ﹤0.01% | 2783 |
|
|
2022
Q4 | $10.3M | Buy |
2,030,492
+108,903
| +6% | +$598K | ﹤0.01% | 2253 |
|
|
2022
Q3 | $9.55M | Buy |
1,921,589
+348,755
| +22% | +$1.59M | ﹤0.01% | 2296 |
|
|
2022
Q2 | $5.85M | Buy |
1,572,834
+24,819
| +2% | +$99.7K | ﹤0.01% | 2616 |
|
|
2022
Q1 | $8.68M | Sell |
1,548,015
-8,586
| -0.6% | -$52.7K | ﹤0.01% | 2447 |
|
|
2021
Q4 | $9.46M | Buy |
1,556,601
+40,345
| +3% | +$303K | ﹤0.01% | 2477 |
|
|
2021
Q3 | $14.8M | Buy |
1,516,256
+46,560
| +3% | +$512K | ﹤0.01% | 2174 |
|
|
2021
Q2 | $21M | Buy |
1,469,696
+805,147
| +121% | +$13.3M | ﹤0.01% | 1927 |
|
|
2021
Q1 | $15.8M | Buy |
664,549
+74,788
| +13% | +$1.94M | ﹤0.01% | 2029 |
|
|
2020
Q4 | $7.86M | Buy |
589,761
+58,015
| +11% | +$558K | ﹤0.01% | 2324 |
|
|
2020
Q3 | $3.69M | Buy |
531,746
+40,518
| +8% | +$404K | ﹤0.01% | 2567 |
|
|
2020
Q2 | $6.03M | Buy |
491,228
+169,729
| +53% | +$958K | ﹤0.01% | 2217 |
|
|
2020
Q1 | $925K | Buy |
321,499
+32,865
| +11% | +$165K | ﹤0.01% | 3053 |
|
|
2019
Q4 | $1.09M | Buy |
288,634
+27,216
| +10% | +$46.3K | ﹤0.01% | 3252 |
|
|
2019
Q3 | $318K | Hold |
261,418
| – | – | ﹤0.01% | 3626 |
|
|
2019
Q2 | $266K | Sell |
261,418
-79,951
| -23% | -$92.2K | ﹤0.01% | 3703 |
|
|
2019
Q1 | $539K | Buy |
341,369
+12,492
| +4% | +$15.7K | ﹤0.01% | 3412 |
|
|
2018
Q4 | $381K | Buy |
328,877
+8,961
| +3% | +$20.5K | ﹤0.01% | 3472 |
|
|
2018
Q3 | $1.18M | Buy |
319,916
+19,809
| +7% | +$62.6K | ﹤0.01% | 3148 |
|
|
2018
Q2 | $918K | Buy |
300,107
+12,518
| +4% | +$46.4K | ﹤0.01% | 3221 |
|
|
2018
Q1 | $1.12M | Buy |
287,589
+3,359
| +1% | +$14.7K | ﹤0.01% | 3070 |
|
|
2017
Q4 | $1.28M | Buy |
284,230
+8,386
| +3% | +$39.7K | ﹤0.01% | 2998 |
|
|
2017
Q3 | $1.51M | Sell |
275,844
-15,657
| -5% | -$96.5K | ﹤0.01% | 2906 |
|
|
2017
Q2 | $2.21M | Buy |
291,501
+34,802
| +14% | +$150K | ﹤0.01% | 2675 |
|
|
2017
Q1 | $911K | Buy |
256,699
+18,685
| +8% | +$92.3K | ﹤0.01% | 3061 |
|
|
2016
Q4 | $1.36M | Buy |
238,014
+6,391
| +3% | +$42.6K | ﹤0.01% | 2840 |
|
|
2016
Q3 | $1.8M | Buy |
231,623
+132,626
| +134% | +$991K | ﹤0.01% | 2626 |
|
|
2016
Q2 | $615K | Buy |
98,997
+10,632
| +12% | +$82.5K | ﹤0.01% | 3129 |
|
|
2016
Q1 | $726 | Buy |
88,365
+2,998
| +4% | +$28.3K | ﹤0.01% | 3047 |
|
|
2015
Q4 | $1.48M | Buy |
85,367
+12,439
| +17% | +$185K | ﹤0.01% | 2665 |
|
|
2015
Q3 | $835K | Buy |
+72,928
| New | +$1.59M | ﹤0.01% | 2965 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Geode Capital Management's IBRX Position: Q1 2026 in Review
Geode Capital Management increased its ImmunityBio (IBRX) stake by 1.4% in Q1 2026, buying an estimated $765K and bringing the position to 8,031,921 shares worth $61.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1385.
Geode Capital Management first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Geode Capital Management held 8,031,921 shares of ImmunityBio worth $61.6M as of Q1 2026.
- Geode Capital Management bought 111,743 ImmunityBio shares in Q1 2026, an estimated $765K.
- ImmunityBio made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1385 holding.
- Geode Capital Management first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.